This site is intended for health professionals only
Friday 26 April 2019
Share |

Topic: liraglutide

January 20, 2015
Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2). Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3). The licence extension for Victoza® (liraglutide) increases clinicians’ prescribing options to help patients with both conditions achieve glucose control.
  • Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2).
  • Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3).
November 24, 2014
The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments.

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments.

 

June 9, 2009
The Lancet publishes direct comparison study between liraglutide and exenatide

teaser

May 6, 2009
Exenatide LAR is a new version of the twice-daily injectable drug Byetta, used to control blood sugar levels

teaser

September 26, 2008
New injectable treatment for type 2 diabetes can improve glucose control

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine